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Weperformdammdanizeddmble+lindpla@3o- 
axltrolledtrialtoeva3uatethesaf~~efficacyof 
4dosesOfintra~ (Iv)diltiazeminthetrea~t 
of pts with atrial fibrillation (A F'IB) or atrial 
flutter (A FUR). Fifty pts (age 63 f 14 yr) with 
mAF+IBorAFIUTatahsartrati (BR) 1120 
received either a I-minute injeetionofplacebo 
5) or diltiazern (0.05 ng&, ~9; 0.15 xq/kg, IFS; 
0.25 m#q, n=lO; 0.45 mg/kJ, n=8) follcwed by 15 
nu.nubs of cdssenmtion. 
inheartrate, 
Tablepamvidesnmn%dmga 
~me,ardmean%~in 
systolic and diastolic bloal pressure ( SBP/DBP) for 
l Wsponsewasdefimdaseither~20% 
inm, m!~1OObp, OrSirlus~~. 
Diltiazem (m/Jay) - - -. 
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THE ELECTROCARDlOGRAPHlC EFFECTS OF ENCAINIDE. 
FLECAINIDE,AND MORICIZINE IN ASUBGROUPOFTHECARDIAC 
ARRHYTHMIA SUPPRESSION 
0.055 versus encainide. 
CAST involved several subcategories of trenunenl based on left ventricular 
, flecainide, and moricizine all had class 
PR and QRS but not JTc), there were 
dXferenccs among le drugs tha1 wexe not accounted for by the IA-IB-IC system 
and indicate the potential weakness of this system. Encainide caused more 
prolongation of ti QRS whereas moricizine shortened the JT interval more than 
the tx9er drugs. These findings indicate the unique nature of ant&rhythmic drugs, 
including drugs within the same subcla;s. 
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SAFETY AND EFFICACY OF INTRAVENOUS SOTALOL IN 
TERMINATING SUPRAVENTRICULAR TACHYARR~~H~lAS 
James L. Cockrell, Wei Fan, Ruey J. Sung, Letterman Army 
Medical Center, San Francisco General Hospital and 
Cardiovascular Research Institute, University of California, San 
Francisco, California, U.S.A. 
Sotalol (S) is a new antiarrhythmic agent with both beta- 
adrenoceptor blocking and class Ill antiarrhythmic properties. 
To assess its efficacy In terminating supraventricular 
tachyarrhythmias (SVT), intravenous S at 1 .O - 1.5 mg/kg was 
administered in 10 minutes to 23 patient8 (pts) during 
electrophysiologic studies. 12 pts manifested orthodromic 
atrioventricular reciprocating tachycardia (AVRT), 6 pts 
atrioventricular nodal reentrant tachyoardia (AVNRT), 3 pts 
atrial flutter-fibrillation (AF) with ventricular preexcitation and 2 
pts atrial tach 
n 15 (65%) Y 
cardia (AT). In 5 f 3 minutes, S terminated SW 
o total 23 
AVNRT, O/3 pts with A P 
ts - 1 O/l 2 pts with AVRT, 416 pts with 
and l/2 pts with AT. In the 8/23 (35%) 
pts in whom SVT could not be terminated, S alowed the 
ventricular rate of SVT by 25Oh (from 166 + 60 to 125 + 39 
beats/min, ~~0.02 . Antiarrhythmic prop&& of S cozld be 
accounted for by d -induced prolongation of effective refractory 
periods of atrium, ventricle, atrioventricular node and accessorv 
g 
athway (+16%, +19%, +19%, and +12%, respectively). w 
uring S infusion, 1 pt experienced transient shortness of 
breath but none developed significant hypotension. Thus, we 
conclude that intravenous S is a safe and effective agent for 
acute treatment of SVT of various mechanisms, and IS useful in 
controlling the ventricular rate of AF with ventricular 
preexcitation by virtue of its depressive action on both 
accessory pathway and atrioventricular node. 
